Patent 9729693
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Zepp North America Inc, Zepp Inc
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
As of May 30, 2026, there are no AIA trial proceedings (Inter Partes Review, Post-Grant Review, or Covered Business Method) on file for US Patent 9,729,693 with the USPTO Open Data Portal. Web searches also did not surface any such proceedings, indicating a complete absence of PTAB challenges for this patent.
Strategic summary
Currently, all claims (1-20) of US Patent 9,729,693 remain untested by AIA trial proceedings. This means that a defendant facing assertion of this patent today is not estopped by 35 U.S.C. § 315(e)(2) from challenging any of the claims based on prior art. All prior-art grounds that could be raised in an IPR or PGR are still available. The absence of PTAB challenges suggests that the patent owner (Zepp Inc.) has not yet faced a petitioner motivated or able to pursue an IPR/PGR, or that any such challenges have not been publicly recorded. Given the active litigation against Oura Health Oy, it is possible that Oura may consider filing an IPR, which would introduce PTAB activity.
Recommended next steps
Since no PTAB activity exists for US Patent 9,729,693, a defendant facing assertion of this patent has a full range of options for challenging its validity at the PTAB.
- Consider filing an IPR/PGR: If facing an infringement claim, a defendant should seriously evaluate the strength of the prior art identified in the "Prior art" section of this analysis and consider filing an Inter Partes Review (IPR). The '693 patent's independent claims (1, 11, 16) were identified as potentially obvious in view of combinations of prior art, specifically:
- US 2015/0265217 A1 (Hong) in view of US 2014/0247151 A1 (Sae-Ueng).
- US 9,167,995 B2 (Al-Ali) in view of US 2014/0247151 A1 (Sae-Ueng).
A robust IPR petition could challenge these claims, potentially leading to their invalidation.
- Monitor for new filings: Keep a close watch on the USPTO PTAB E2E system for any newly filed petitions against US 9,729,693, especially from the current defendant in the co-pending district court litigation (Oura Health Oy).
- Review district court invalidity contentions: If the patent is being asserted in district court litigation, scrutinize the defendant's invalidity contentions to understand which prior art references they are relying on and for which claims. This can inform the strategy for a potential PTAB challenge.
Generated 5/30/2026, 12:48:49 AM